14,593 results match your criteria: "Fax: +49 221-47886851; Max Planck Institute for Metabolism Research[Affiliation]"

Anti-Hypertensives Reduce the Rate of Alzheimer's Disease Progression: A Cohort Study Linked with Genetic and Neuropathological Analyses.

J Prev Alzheimers Dis

November 2024

Zohara Sternberg, PhD, Clinical Associate Professor of Neurology, Buffalo Medical Center, Buffalo, NY, 14203, Tel: 716-8597540, Fax: 716-8592430, 859-7573, Email:

Article Synopsis
  • Arterial hypertension is linked to the development and progression of dementia, especially in Alzheimer's disease, but the impact of anti-hypertensive treatments on dementia progression is not well understood.* -
  • A study found that using anti-hypertensive medications was associated with a slower progression of dementia symptoms and better overall survival rates, with specific drug classes showing notable effects.* -
  • The research suggests that certain combinations of anti-hypertensives may reduce brain pathology associated with Alzheimer's, indicating potential pathways to slow down dementia progression.*
View Article and Find Full Text PDF

Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure.

J Prev Alzheimers Dis

November 2024

Fred B. Ketchum, Department of Neurology, School of Medicine and Public Health, University of Wisconsin, Madison, 1685 Highland Avenue, Madison, WI 53705, USA, Phone (608) 265-5523, Fax (608) 263-0412,

Background: Biomarker results are increasingly disclosed in research and clinical settings, but less is known about how individuals interpret their results or concerns raised during the disclosure visit that may need to be addressed by clinicians to ensure appropriate disclosure.

Methods: Fifty-two cognitively unimpaired older adults aged 65 to 89 years old from the Wisconsin Registry for Alzheimer's Prevention, who had undergone an amyloid PET scan in the previous 18 months, were enrolled in the disclosure substudy. After ensuring psychological readiness, trained study clinicians disclosed amyloid PET results using a structured protocol.

View Article and Find Full Text PDF

Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center.

J Prev Alzheimers Dis

November 2024

Kenneth G. Pugh, MD, MSc, Norton Neuroscience Institute Memory Center, Norton Healthcare, Norton Medical Plaza III- Brownsboro, Suite 300, 4915 Norton Healthcare Blvd. Louisville, KY 40241 U.S.A., (502) 394-6460 (Office); (502) 394-6465 (FAX), E-mail:

Article Synopsis
  • The FDA approved lecanemab (Leqembi®) on July 6, 2023, for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease, with early experiences shared from a regional medical center.
  • A retrospective study at the Norton Neuroscience Institute Memory Center involved 71 patients, all diagnosed with Alzheimer’s through cerebrospinal fluid biomarkers, most of whom were older, predominantly female, and referred by their primary care providers.
  • The study found that 24% of patients experienced amyloid-related imaging abnormalities (ARIA) after treatment, with differences noted between those homozygous and heterozygous for the ApoE4 genotype.
View Article and Find Full Text PDF

Background: In February 2022, a novel antiviral for the treatment of COVID-19, nirmatrelvir/ritonavir (Paxlovid), was approved by Health Canada and made available to patients in British Columbia (BC). BC community pharmacists did not prescribe nirmatrelvir/ritonavir, but dispensing involved a detailed assessment with close attention to drug-drug interactions and patient monitoring. As the nirmatrelvir/ritonavir service was unique in BC, and not all pharmacists participated in the program, it is important to evaluate the perspectives of all the pharmacists who were affected so that lessons learned from the program can inform future pandemic planning and government initiatives.

View Article and Find Full Text PDF

Impact of Ferulated Arabinoxylans from Maize Bran on Farinograph and Pasting Properties of Wheat Flour Blends.

Foods

October 2024

Whistler Center for Carbohydrate Research, Department of Food Science, Purdue University, West Lafayette, IN 47907, USA.

This research explores the extraction of ferulated arabinoxylans (FAXs) from maize bran and their incorporation into wheat flour to assess their impact on rheological and pasting properties. Flour blends were prepared with FAX concentrations of 0%, 2%, 4%, 6%, 8%, and 10%, and these blends were then evaluated using farinograph, mixograph, micro-extensibility, and viscosity analyses. The results indicated that farinograph water absorption increased significantly ( ≤ 0.

View Article and Find Full Text PDF

Living fully, choosing wisely: Exploring patient-centred approaches to palliative care and MAiD - Part I.

Can Oncol Nurs J

November 2024

Associate Professor, Faculty of Health, Community and Education Calgary, Mount Royal University, 4825 Mount Royal Gate SW, Calgary, Alberta Ph: (403) 390-8141/Fax: (403) 440-6203,

With increasing numbers of individuals presenting with advanced cancer, strong recommendations for the integration of palliative care in oncology, and the availability and acceptance of medical assistance in dying, oncology nurses must be informed and prepared to provide patient-centred care in advanced cancer. This is part one of a two-part case report presenting an exploration of early palliative care and medical assistance in dying in the setting of advanced cancer. It focuses on the patient and family experience throughout the illness trajectory, from diagnosis to death, and incorporates some of the common challenges seen in supporting someone with advanced cancer.

View Article and Find Full Text PDF

Recent changes to legislation in British Columbia (BC) have expanded the scope of pharmacist-provided services to include pharmacist prescribing for minor ailments and contraception (PPMAC). The purpose of this study was to gather community-based pharmacists' perspectives on these changes to practice. This was a cross-sectional online survey study.

View Article and Find Full Text PDF

Barriers to obtaining and using interoperable information among non-federal acute care hospitals.

J Am Med Inform Assoc

January 2025

Office of the Assistant Secretary for Technology Policy, US Department of Health and Human Services, Washington, DC 20201, United States.

Objective: To understand barriers to obtaining and using interoperable information at US hospitals.

Materials And Methods: Using 2023 nationally representative survey data on US hospitals (N = 2420), we examined major and minor barriers to exchanging information with other organizations, and how barriers vary by hospital characteristics and methods used to obtain information. Using a series of regression models, we examined how hospital experiences with barriers relate to routine use of information at responding hospitals.

View Article and Find Full Text PDF

Improving tabular data extraction in scanned laboratory reports using deep learning models.

J Biomed Inform

November 2024

Section of Biomedical Informatics and Data Science, School of Medicine, Yale University, New Haven, CT 06510, USA. Electronic address:

Objective: Medical laboratory testing is essential in healthcare, providing crucial data for diagnosis and treatment. Nevertheless, patients' lab testing results are often transferred via fax across healthcare organizations and are not immediately available for timely clinical decision making. Thus, it is important to develop new technologies to accurately extract lab testing information from scanned laboratory reports.

View Article and Find Full Text PDF

Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease.

J Prev Alzheimers Dis

October 2024

Nikki H. Stricker, Ph.D., ABPP-CN, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; 507-284-2649 (phone), 507-284-4158 (fax), (email).

Background: Easily accessible and self-administered cognitive assessments that can aid early detection for Alzheimer's disease (AD) dementia risk are critical for timely intervention.

Objectives/design: This cross-sectional study investigated continuous associations between Mayo Test Drive (MTD) - a remote, self-administered, multi-device compatible, web-based cognitive assessment - and AD-related imaging biomarkers.

Participants/setting: 684 adults from the Mayo Clinic Study of Aging and Mayo Clinic Alzheimer's Disease Research Center participated (age=70.

View Article and Find Full Text PDF

Associations of Blood Pressure Trajectories with Subsequent Cognitive Decline, Dementia and Mortality.

J Prev Alzheimers Dis

October 2024

Wuxiang Xie, Peking University Clinical Research Institute, Peking University First Hospital, No. 38 Xueyuan Road, Haidian District, 100191, Beijing, China. Telephone: +86-10-82805564-622; Fax: +86-10-62015547; E-mail: Fanfan Zheng, Department of Clinical Nursing, School of Nursing, Chinese Academy of Medical Sciences and Peking Union Medical College, 33 Ba Da Chu Rd, Shijingshan District, 100144, Beijing, China. E-mail:

Background: Hypertension may harm cognitive performance, but the potential correlates of longitudinal patterns of blood pressure (BP), especially diastolic BP (DBP), to cognition have been unclear.

Objectives: To examine long-term BP trajectories in relation to subsequent cognitive decline, incident dementia and all-cause mortality in the general population.

Design: Population-based cohort study.

View Article and Find Full Text PDF

Estimating Socio-Economic Status for Alzheimer's Disease Trials.

J Prev Alzheimers Dis

October 2024

Dorene M Rentz, PsyD, Department of Neurology, Brigham and Women's Hospital, 60 Fenwood Road, 9016S, Boston, MA 02115, USA, Email: Telephone: 617-732-2385, FAX: 617-738-9122.

Introduction: Metrics of a participant's socioeconomic status (SES) are not routinely collected or standardized in clinical trials. This omission limits the ability to evaluate the generalizability of trial results and restricts clinicians from confidently interpreting the efficacy of new treatments across important sub-populations.

Methods: We adapted an SES measure of social disparity; the Hollingshead Two Factor Index of Social Position, which combines education and occupation into a single metric.

View Article and Find Full Text PDF

Risk of Dementia in Korean Vietnam War Veterans.

J Prev Alzheimers Dis

October 2024

Won-Jun Choi, M.D., MPH, Ph.D. Department of Occupational and Environmental Medicine, Gil Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774beon-gil, Namdong-gu, Incheon, Republic of Korea, Postal code: 21565, E-mail: Tel: +82-32-460-8866, Fax: +82-32-460-2363.

Article Synopsis
  • More and more people are getting dementia, especially Vietnam War veterans in Korea who might have been exposed to harmful chemicals during the war.
  • A study looked at Vietnam War veterans and compared their chances of getting dementia to other people in Korea.
  • The results showed that veterans are at a higher risk for different types of dementia, suggesting these risks could be linked to the chemicals they encountered during the war.
View Article and Find Full Text PDF

Evaluating the Causal Effect of Type 2 Diabetes on Alzheimer's Disease Using Large-Scale Genetic Data.

J Prev Alzheimers Dis

October 2024

Fuquan Zhang Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, 264 Guangzhou Road, Nanjing, 210029, China, Tel: 862582296593, Fax: 862582296593.

Background: Alzheimer's disease (AD) has a high comorbidity with type 2 diabetes (T2D). However, there is still some controversy over whether T2D has a causal impact on AD at present.

Objectives: We aimed to reveal whether T2D has a causal effect on AD using large-scale genetic data.

View Article and Find Full Text PDF

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.

J Prev Alzheimers Dis

October 2024

Yasuo Toda, Biogen Japan Ltd., 1-4-1 Nihonbashi, Chuo-ku, Tokyo 103-0027, Email: Phone: +81-3-3275-2074, Fax: +81-3-3275-1920, ORCID: 0000-0002-8737-5256.

Article Synopsis
  • The global incidence of dementia, particularly Alzheimer's disease (AD), is increasing, prompting the need for effective treatments like aducanumab, which targets amyloid beta involved in AD.
  • Aducanumab was approved by the FDA in June 2021 for treating early AD through an accelerated approval process, supported by data from two global phase 3 studies, EMERGE and ENGAGE.
  • In these studies, Japanese participants with a confirmed diagnosis of mild cognitive impairment or mild AD dementia were evaluated for the drug's efficacy, safety, and pharmacokinetics, with results aligning closely with the overall findings.
View Article and Find Full Text PDF

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy.

J Prev Alzheimers Dis

October 2024

Rachel L. Nosheny, Ph.D., Assistant Professor, University of California, San Francisco, Department of Psychiatry, San Francisco VA Medical Center, 4150 Clement Street (114M), San Francisco, CA 94121, Tel: 650-468-0619, Fax: 415-668-2864, email:

Background: Recently, two monoclonal antibodies that lower amyloid plaques have shown promising results for the treatment of Mild Cognitive Impairment (MCI) and mild dementia due to Alzheimer's disease (AD). These treatments require the identification of cognitively impaired older adults with biomarker evidence of AD pathology using CSF biomarkers or amyloid-PET. Previous studies showed plasma biomarkers (plasma Aβ42/Aβ40 and p-tau181) and hippocampal volume from structural MRI correlated with brain amyloid pathology.

View Article and Find Full Text PDF

Prevalence Estimation of Dementia/Alzheimer's Disease Using Health and Retirement Study Database in the United States.

J Prev Alzheimers Dis

October 2024

Amir Abbas Tahami Monfared, MD, PhD, ORCID: https://orcid.org/0000-0003-4003-3192, Eisai, Inc., 200 Metro Blvd, Nutley, NJ 07110, USA, Tel.: (201) 746-2112, Fax: (732) 791-1088, E-mail:

Article Synopsis
  • The study examines the prevalence and severity of Alzheimer's disease (AD) and mild cognitive impairment (MCI) in the U.S. using data from the Health and Retirement Study (HRS).
  • It analyzes the data from four surveys conducted between 2014 and 2020, focusing on respondents aged over 50 years, with the goal of providing accurate estimates for effective management of AD.
  • Results showed that while the diagnosed prevalence of AD was around 1-1.3%, cognitive performance assessments indicated that 23-27% of participants had scores indicative of dementia, with a consistent prevalence of 23% for all-cause MCI across the surveys.
View Article and Find Full Text PDF
Article Synopsis
  • * A cluster randomised controlled trial will be conducted in Sydney to test a new integrated approach for secondary fracture prevention in primary care settings, which includes alerts to doctors and management guidelines for osteoporotic fractures.
  • * The primary goal of the trial is to measure how many patients get bone density scans or prescriptions for osteoporosis treatment within three months of an initial fracture diagnosis, while also tracking additional outcomes related to osteoporosis management.
View Article and Find Full Text PDF

From Fax to Secure File Transfer Protocol: The 25-Year Evolution of Real-Time Syndromic Surveillance in England.

J Med Internet Res

September 2024

Real-time Syndromic Surveillance Team, UK Health Security Agency, Birmingham, United Kingdom.

The purpose of syndromic surveillance is to provide early warning of public health incidents, real-time situational awareness during incidents and emergencies, and reassurance of the lack of impact on the population, particularly during mass gatherings. The United Kingdom Health Security Agency (UKHSA) currently coordinates a real-time syndromic surveillance service that encompasses 6 national syndromic surveillance systems reporting on daily health care usage across England. Each working day, UKHSA analyzes syndromic data from over 200,000 daily patient encounters with the National Health Service, monitoring over 140 unique syndromic indicators, risk assessing over 50 daily statistical exceedances, and taking and recommending public health action on these daily.

View Article and Find Full Text PDF

Interventions for tobacco use cessation in people living with HIV.

Cochrane Database Syst Rev

August 2024

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Background: The prevalence of tobacco use among people living with HIV (PLWH) is up to four times higher than in the general population. Unfortunately, tobacco use increases the risk of progression to AIDS and death. Individual- and group-level interventions, and system-change interventions that are effective in helping PLWH stop using tobacco can markedly improve the health and quality of life of this population.

View Article and Find Full Text PDF

Purpose: To compare the postoperative pain score, opioid consumption, and blood loss in knee osteoarthritis patients who underwent unilateral primary total knee arthroplasty with and without intraoperative cold solution irrigation.

Method: In total, 70 knee osteoarthritis patients were randomly included in the study and allocated into 2 groups. The first group was irrigated intraoperatively with a cold solution and the second group was irrigated intraoperatively with a room-temperature solution.

View Article and Find Full Text PDF

Integrated Service Delivery Model in Primary Care to Improve Frailty in Older Malaysians: GeKo Integrated Service Delivery.

J Frailty Aging

July 2024

Sally Suriani Ahip, Kota Samarahan Health Clinic, Jalan Datuk Mohammad Musa, 94300 Kota Samarahan, Sarawak, Malaysia, Email address: Telephone: +60125880709, Fax number: +6082673632.

Background: This study aimed to evaluate the implementation stage of Malaysia's GeKo-Integrated Service Delivery (ISD) model for frailty management in primary care and explore its effectiveness in improving frailty scores.

Methods: The implementation stage of Malaysia's first three GeKo- ISD clinics was assessed using the WHO-ICOPE (Integrated Care of the Older Persons) scorecard. This involved evaluating documents related to the GeKo services and conducting in-depth interviews with key informants identified from those documents.

View Article and Find Full Text PDF

Frailty Trajectories and Its Associated Factors in Japanese Older Adults.

J Frailty Aging

July 2024

Akihiko Kitamura, Research Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology; 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan; Phone: +81(3)3964-3241, Fax: +81(3)3964-4776; Email:

Background: Associated factors for frailty development according to age group remain unclear.

Objectives: To identify frailty score trajectories among community-dwelling older Japanese individuals and examine their associated factors.

Design: 13-year longitudinal study.

View Article and Find Full Text PDF

Association of Finger Tapping Movements with Frailty Status in older Japanese Adults: A Cross-Sectional Study.

J Frailty Aging

July 2024

Prof Akiko Tamakoshi MD, PhD, Department of Public Health, Hokkaido University Graduate School of Medicine, N15W7, Kita-ku, Sapporo 060-0812, Japan, Tel: +81 11 7065068; Fax: +81 11 7065068, E-mail:

Background: Finger tapping impairment and frailty share overlapping pathophysiology and symptoms in older adults, however, the relationship between each other has not been previously studied.

Objectives: To investigate how finger tapping movements correlate with frail status in older Japanese adults.

Design, Setting, And Participants: Data were from a cross-sectional study called the Cognition and Activity in Rural Environment of Hokkaido Senior Survey 2018.

View Article and Find Full Text PDF

The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test.

J Prev Alzheimers Dis

July 2024

Agnes S. Chan, Room 355, Sino Building, Department of Psychology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China, Email: Telephone: (852) 3943-6654, Fax: (852) 2603-5019.

Introduction: The Shape Trail Test (STT) was developed based upon the Trail Making Test, as a culture-neutral test for measuring processing speed and mental flexibility. This study aims to evaluate the accuracy and validity of this five-minute test for differentiating individuals with normal cognition (NC), subjective memory impairment (SMI), and mild cognitive impairment (MCI).

Method: The study included 210 participants aged 50-80 years, with 70 participants in each group matched for age, education, and gender.

View Article and Find Full Text PDF